Alkermes PLC (ALKS) Position Maintained by Glenmede Trust Co. NA
Glenmede Trust Co. NA held its stake in Alkermes PLC (NASDAQ:ALKS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,040 shares of the company’s stock at the end of the first quarter. Glenmede Trust Co. NA’s holdings in Alkermes PLC were worth $446,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of ALKS. Russell Investments Group Ltd. acquired a new stake in Alkermes PLC during the fourth quarter worth $439,000. Dimensional Fund Advisors LP raised its stake in Alkermes PLC by 4.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 191,640 shares of the company’s stock worth $10,651,000 after buying an additional 7,797 shares in the last quarter. Norges Bank acquired a new stake in Alkermes PLC during the fourth quarter worth $44,274,000. Camber Capital Management LLC raised its stake in Alkermes PLC by 6.7% in the fourth quarter. Camber Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $55,580,000 after buying an additional 62,700 shares in the last quarter. Finally, Opus Point Partners Management LLC raised its stake in Alkermes PLC by 0.8% in the fourth quarter. Opus Point Partners Management LLC now owns 82,296 shares of the company’s stock worth $4,574,000 after buying an additional 619 shares in the last quarter. Institutional investors own 97.21% of the company’s stock.
Shares of Alkermes PLC (ALKS) opened at 57.42 on Wednesday. Alkermes PLC has a 12 month low of $41.93 and a 12 month high of $63.40. The firm has a 50-day moving average of $58.44 and a 200-day moving average of $57.27. The company’s market capitalization is $8.80 billion.
Alkermes PLC (NASDAQ:ALKS) last issued its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.07. The firm had revenue of $191.80 million during the quarter, compared to analysts’ expectations of $195.79 million. Alkermes PLC had a negative return on equity of 9.76% and a negative net margin of 25.61%. The firm’s quarterly revenue was up 22.3% on a year-over-year basis. During the same period last year, the firm posted ($0.16) earnings per share. On average, equities analysts predict that Alkermes PLC will post ($0.04) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Alkermes PLC (ALKS) Position Maintained by Glenmede Trust Co. NA” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/07/12/alkermes-plc-alks-position-maintained-by-glenmede-trust-co-na.html.
ALKS has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “neutral” rating and issued a $51.00 target price on shares of Alkermes PLC in a report on Thursday, March 16th. Cowen and Company restated a “positive” rating and issued a $65.00 target price on shares of Alkermes PLC in a report on Tuesday, March 21st. Jefferies Group LLC restated a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a report on Monday, April 3rd. Morgan Stanley restated an “equal weight” rating and issued a $62.00 target price on shares of Alkermes PLC in a report on Monday, April 24th. Finally, J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a report on Thursday, April 27th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $63.10.
In other Alkermes PLC news, CMO Elliot Ehrich sold 10,000 shares of Alkermes PLC stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $56.60, for a total value of $566,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 65,071 shares of the company’s stock, valued at $3,683,018.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shane Cooke sold 6,500 shares of Alkermes PLC stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $60.05, for a total transaction of $390,325.00. Following the completion of the transaction, the insider now directly owns 78,448 shares of the company’s stock, valued at $4,710,802.40. The disclosure for this sale can be found here. Insiders sold 149,500 shares of company stock valued at $8,652,675 over the last ninety days. Corporate insiders own 5.34% of the company’s stock.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Stock Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related stocks with our FREE daily email newsletter.